Molecular Pathology of
Gallbladder Cancer
Gallbladder Cancer
|
Molecular Pathology of Gallbladder Cancer |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KRAS | Ras Signal Transduction Pathway |
20% | ||||||||||
| p16 | 31% | |||||||||||
| p53 | p53 Tumor Suppressor Pathway |
36% | ||||||||||
| Pi3-kinase | PI3-Kinase Signaling |
Gallbladder Carcinomas | 4% |
| See Clinical Trials in in the TTC Database |
| CANCER.GOV PDQ® - Standard Treatments for Gallbladder Cancer |